Lipid Disorders
Conference Coverage
Nutrition expert to heart patients: ‘Eat some cheese’
“A diet including cheese should be recommended for all to prevent and manage type 2 diabetes and cardiovascular disease,” according to Arne Astrup...
Conference Coverage
High-intensity statins cut amputations and mortality in PAD
NEW ORLEANS – High-intensity statin therapy in patients with peripheral artery disease saves lives and limbs.
Conference Coverage
VIDEO: New antisense inhibitor nets impressive reductions in lipids
NEW ORLEANS – A new antisense inhibitor to angiopoietinlike protein 3 (ANGPTL3) reduces lipids in healthy adults with elevated triglyceride levels...
From the Journals
Mild, moderate hypertriglyceridemia raises pancreatitis risk
Mild to moderate hypertriglyceridemia, not just severe hypertriglyceridemia, is associated with increased risk of acute pancreatitis, according to...
From the Journals
Statins protect against Alzheimer’s in most patients
Statins taken to reduce cholesterol also protect most patients against Alzheimer’s disease, but the decrease in risk varies across different...
Conference Coverage
Nonalcoholic fatty liver disease accelerates brain aging
TORONTO – NAFLD seems to accelerate physical brain aging by up to 7 years, according to a new subanalysis of the ongoing Framingham Heart Study....
Article
Examining the safety of lipid-lowering drugs in pregnancy
Lipid-lowering medications are some of the most commonly prescribed drugs in the United States. But while much is known about their general safety...
News from the FDA/CDC
Empagliflozin first antidiabetes drug to gain cardioprotective indication
Empagliflozin is the first antidiabetes medication to be approved for reducing the risk of cardiovascular death in patients with type 2 diabetes...
Conference Coverage
VIDEO: MILANO-PILOT marks end of the road for HDL mimetic
Among 120 patients with recent acute coronary syndrome, a mimetic known as MDCO-216 was no better than placebo at reducing coronary plaque...
Conference Coverage
NAFLD can regress with weight loss, activity
BOSTON – All phenotypes of nonalcoholic fatty liver disease can progress or regress even without pharmacologic intervention, according to a...
Conference Coverage
GLAGOV finds evolocumab plus statin drives unprecedented plaque regression
NEW ORLEANS – Adding evolocumab to statin therapy resulted in unprecedented coronary atheromatous plaque regression in the GLAGOV study.